Physician profile
Stephen Veluz
NPI 1730293192
$503.73
in general payments reported to CMS, 2019-2025
11 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.85 · 2021: $125 · 2022: $49.37 · 2023: $39.60 · 2024: $125 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $308.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $88.34 | 2022-2025 | Eliquis |
| Abbvie INC. | $80.75 | 2024-2025 | |
| Sk Life Science, INC. | $78.79 | 2021 | |
| Janssen Pharmaceuticals, INC | $67.39 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $53.31 | 2022-2023 | |
| Urgo Medical North America, LLC | $30.39 | 2025 | Urgoclean Ag |
| Microtransponder, INC. | $26.83 | 2024 | |
| Boston Scientific Corporation | $25.66 | 2024 | Watchman Flx |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.51 | 2025 | Rejoyn |
| Merck Sharp & Dohme LLC | $18.57 | 2025 | Verquvo |
| Kci USA, INC. | $13.19 | 2023 | V.A.C. Veraflo Cleanse Choice |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Veluz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.